Seres Therapeutics (MCRB) Reports Q1 Revenues Above Consensus
Get Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of $, versus ($0.76) reported last year. Revenue for the quarter came in at $3.77 million versus the consensus estimate of $2.39 million.
Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres commented: “Seres has made significant progress in advancing our field-leading microbiome therapeutic pipeline. We continue to enroll the SER-109 Phase 3 study in patients with multiply recurrent C. difficile infection. We have had positive dialogues with FDA to support further development of SER-287 in Ulcerative Colitis and we continue to plan to initiate a next SER-287 study in mid-2018. Seres also presented important preclinical data that further elucidate how microbiome therapy impacts immune biology and checkpoint inhibitor activity. Dialogue with the FDA is ongoing regarding immuno-oncology related development plans, and we expect initiation of the SER-401 microbiome therapy clinical study later this year.”
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Volcon (VLCN) Reports 2023 Operational and Financial Results
- NRx Pharmaceuticals (NRXP) Reports Prelim FY23 Results
- Pineapple Energy Inc. (PEGY) Misses Q4 EPS by 8c
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!